Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bayer paid $240M upfront plus up to $360M milestones to consolidate full ownership of BlueRock; the deal extends Bayer's cell-therapy thesis from the Versant…
iPSC-derived neurons solve the variability problems that plagued earlier fetal-tissue transplantation; the Bayer deal 'signals major pharmaceutical confidence…
FDA grants Orphan Drug Designation to OpCT-001 for retinitis pigmentosa (Jan 22, 2026); OpCT-001 also holds FDA Fast Track (Feb 2025).
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Bayer acquired the remaining ~59.2% of BlueRock Therapeutics it did not already own for $240M upfront plus up to $360M in milestones (~$600M total); the deal closed August 13, 2019. BlueRock's iPSC-derived cell-therapy platform engineers replacement cells for disease. As of 2026 the platform has materially advanced: lead asset bemdaneprocel (BRT-DA01), iPSC-derived dopaminergic neurons for Parkinson's disease, began the registrational Phase III exPDite-2 trial (~102 patients, randomized double-blind sham-surgery-controlled) with the first patient treated in September 2025, and holds FDA Fast Track (2021), RMAT (2024) and Japan SAKIGAKE (Dec 2025) designations. A second asset, OpCT-001, an iPSC-derived photoreceptor cell therapy for primary photoreceptor disease (retinitis pigmentosa), entered a Phase 1/2a trial (first patient July 2025) and received FDA Orphan Drug Designation (Jan 2026), extending the platform from neurology into ophthalmology.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / BlueRock Therapeutics LP (this deal) | 2019 | $600M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2019 deals · Bayer AG deals · Cardiovascular deals